Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
IgA Nephropathy in 2025: Year in Review
1.
When does a melanoma metastasize? Implications for management
2.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
3.
In MDS at Lower Risk, Novel Therapy Diminished Transfusion Dependency.
4.
As pesticides and wildfires rise, kids with cancer need resources
5.
Study offers clearer picture of childhood brain tumor survival
1.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
2.
Genetic Screening: A Game Changer in Cancer Prevention
3.
Everything You Need to Know About Normal Potassium Levels
4.
Mechanisms, Efficacy, and Survival Outcomes in AML, Squamous Cell Carcinoma, & Non-Hodgkin Lymphoma
5.
Multiple Myeloma: Understanding the Basics
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
5.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation